CO107 Resource Use Associated with Alpelisib for the Treatment of Patients with PROS: A Modeling Approach

To model and assess the impact introduction of alpelisib (i.e., world with alpelisib) compared with current standard of care (SoC, i.e., world without alpelisib) would have on surgery rates for the treatment of adult and pediatric patients, 2 years of age and older, with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) in France.

Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: N. Petrica, K. Cottard, P. Foss, S. Palladino, N. Yasar, J.F. Ricci Source Type: research